middle.news
Race Oncology Launches Dual Trials to Combat AML and Lung Cancer Resistance
9:20am on Monday 17th of November, 2025 AEDT
•
Healthcare
Read Story
Race Oncology Launches Dual Trials to Combat AML and Lung Cancer Resistance
9:20am on Monday 17th of November, 2025 AEDT
Key Points
Initiation of Phase 3 AML trial bridging RC110 to RC220
Launch of Phase 1a/b NSCLC trial targeting EGFR mutation resistance
RC220’s novel G4-binding mechanism underpins new lung cancer strategy
Funding linked to shareholder exercise of piggyback options
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Racura Oncology (ASX:RAC)
OPEN ARTICLE